CLM Stock Overview
A biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Clearside Biomedical, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.09 |
52 Week High | US$1.41 |
52 Week Low | US$0.81 |
Beta | 2.35 |
11 Month Change | 0% |
3 Month Change | 7.92% |
1 Year Change | n/a |
33 Year Change | -80.88% |
5 Year Change | n/a |
Change since IPO | -89.17% |
Recent News & Updates
Recent updates
Shareholder Returns
CLM | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 0% | 3.1% | 4.5% |
1Y | n/a | -12.1% | 13.4% |
Return vs Industry: Insufficient data to determine how CLM performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CLM performed against the German Market.
Price Volatility
CLM volatility | |
---|---|
CLM Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 5.2% |
Market Average Movement | 5.0% |
10% most volatile stocks in DE Market | 11.8% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CLM has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CLM's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2011 | 30 | George Lasezkay | clearsidebio.com |
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
Clearside Biomedical, Inc. Fundamentals Summary
CLM fundamental statistics | |
---|---|
Market cap | €87.71m |
Earnings (TTM) | -€29.97m |
Revenue (TTM) | €6.74m |
13.0x
P/S Ratio-2.9x
P/E RatioIs CLM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CLM income statement (TTM) | |
---|---|
Revenue | US$7.52m |
Cost of Revenue | US$142.00k |
Gross Profit | US$7.38m |
Other Expenses | US$40.84m |
Earnings | -US$33.46m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.45 |
Gross Margin | 98.11% |
Net Profit Margin | -444.66% |
Debt/Equity Ratio | -165.2% |
How did CLM perform over the long term?
See historical performance and comparison